

ASTROTECH Corp \WA\
Form 10-Q
May 07, 2012
[Table of Contents](#)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2012

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission File Number: 001-34426

Astrotech Corporation

(Exact name of registrant as specified in this charter)

Washington
(State or other jurisdiction of
incorporation or organization)

401 Congress Avenue, Suite 1650

Austin, Texas 78701

(Address of principal executive offices and zip code)

(512) 485-9530

(Registrant's telephone number, including area code)

91-1273737
(I.R.S. Employer
Identification No.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐ (Do not check if a smaller reporting company)

Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☒

As of May 5, 2012 there were 19,497,560 shares of the registrant's common stock outstanding.

Table of Contents

ASTROTECH CORPORATION AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10-Q

TABLE OF CONTENTS

<u>PART I: FINANCIAL INFORMATION</u>	Page
	3
<u>ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</u>	3
<u>ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	19
<u>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>	23
<u>ITEM 4. CONTROLS AND PROCEDURES</u>	23
<u>PART II: OTHER INFORMATION</u>	24
<u>ITEM 1. LEGAL PROCEEDINGS</u>	24
<u>ITEM 1A. RISK FACTORS</u>	24
<u>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</u>	24
<u>ITEM 3. DEFAULTS UPON SENIOR SECURITIES</u>	24
<u>ITEM 4. MINE SAFETY DISCLOSURES</u>	24
<u>ITEM 5. OTHER INFORMATION</u>	24
<u>ITEM 6. EXHIBITS</u>	24
Exhibit 31.1	
Exhibit 31.2	
Exhibit 32	
EX-101 INSTANCE DOCUMENT	
EX-101 SCHEMA DOCUMENT	
EX-101 CALCULATION LINKBASE DOCUMENT	
EX-101 LABELS LINKBASE DOCUMENT	
EX-101 PRESENTATION LINKBASE DOCUMENT	

Table of Contents**PART I: FINANCIAL INFORMATION**

ITEM 1. Condensed Consolidated Financial Statements

ASTROTECH CORPORATION AND SUBSIDIARIES**Condensed Consolidated Balance Sheets**

(In thousands, except share data)

	March 31, 2012 (unaudited)	June 30, 2011
Assets		
Current assets		
Cash and cash equivalents	\$ 15,840	\$ 14,994
Accounts receivable, net	1,704	2,429
Prepaid expenses and other current assets	1,080	963
Short-term note receivable	675	
Total current assets	19,299	18,386
Property & equipment, net	36,903	38,418
Long-term note receivable		675
Other assets, net	113	141
Total assets	\$ 56,315	\$ 57,620
Liabilities and Stockholders' Equity		
Current liabilities		
Accounts payable	\$ 1,732	\$ 757
Accrued liabilities	3,308	1,342
Deferred revenue	6,532	10,919
Term note payable	368	348
Total current liabilities	11,940	13,366
Deferred revenue	891	274
Term note payable, net of current portion	6,135	6,422
Total liabilities	18,966	20,062
Stockholders' equity		
Preferred stock, no par value, convertible, 2,500,000 authorized shares, 0 issued and outstanding shares, at March 31, 2012 and June 30, 2011		
Common stock, no par value, 75,000,000 shares authorized; 19,134,907 and 18,339,609 shares issued at March 31, 2012 and June 30, 2011	183,712	183,712
Treasury stock, 311,660 shares at cost	(237)	(237)
Additional paid-in capital	1,561	1,104
Accumulated deficit	(150,381)	(148,942)
Noncontrolling interest	2,694	1,921
Total stockholders' equity	37,349	37,558

Total liabilities and stockholders' equity	\$ 56,315	\$ 57,620
---	------------------	------------------

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

ASTROTECH CORPORATION AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

	Three Months Ended March 31, 2012 2011 (unaudited)		Nine Months Ended March 31, 2012 2011 (unaudited)	
Revenue	\$ 10,013	\$ 5,720	\$ 18,529	\$ 15,667
Cost of revenue	6,770	3,142	12,804	10,066
Gross profit	3,243	2,578	5,725	5,601
Operating expenses:				
Selling, general and administrative	1,814	1,941	5,451	6,367
Research and development	475	1,256	1,979	2,962
Total operating expenses	2,289	3,197	7,430	9,329
Income (loss) from operations	954	(619)	(1,705)	(3,728)
Interest and other expense, net	(69)	(70)	(202)	(208)
Income (loss) before income taxes	885	(689)	(1,907)	(3,936)
Income tax expense	(5)	(5)	(17)	(16)
Net income (loss)	880	(694)	(1,924)	(3,952)
Less: Net loss attributable to noncontrolling interest	(134)	(248)	(486)	(781)
Net income (loss) attributable to Astrotech Corporation	\$ 1,014	\$ (446)	\$ (1,438)	\$ (3,171)
Net income (loss) per share attributable to Astrotech Corporation, basic	\$ 0.05	\$ (0.02)	\$ (0.08)	\$ (0.18)
Weighted average common shares outstanding, basic	18,764	17,958	18,448	17,744
Net income (loss) per share attributable to Astrotech Corporation, diluted	\$ 0.05	\$ (0.02)	\$ (0.08)	\$ (0.18)
Weighted average common shares outstanding, diluted	19,152	17,958	18,448	17,744

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents**ASTROTECH CORPORATION AND SUBSIDIARIES****Condensed Consolidated Statements of Cash Flows**

(In thousands)

	Nine Months Ended March 31, 2012 2011 (unaudited)	
Cash flows from operating activities		
Net loss	\$ (1,924)	\$ (3,952)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Stock-based compensation	815	927
Asset impairment	200	
Depreciation and amortization	1,742	1,697
Changes in assets and liabilities:		
Accounts receivable	725	2,658
Deferred revenue	(3,770)	1,742
Accounts payable	975	(73)
Other assets and liabilities	1,835	(1,511)
Net cash provided by operating activities	598	1,488
Cash flows from investing activities		
Purchases of property, equipment and leasehold improvements	(385)	(621)
Net cash used in investing activities	(385)	(621)
Cash flows from financing activities		
Term loan repayment		(3,356)
Senior convertible notes repayment		(5,111)
Proceeds from term loan		6,943
Proceeds from issuance of common stock		148
Term loan payment	(267)	(87)
State of Texas funding	900	
Net cash provided by (used in) financing activities	633	(1,463)
Net change in cash and cash equivalents	846	(596)
Cash and cash equivalents at beginning of period	14,994	8,085
Cash and cash equivalents at end of period	\$ 15,840	\$ 7,489
Supplemental disclosures of cash flow information:		
Cash paid for interest	\$ 200	\$ 297

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

ASTROTECH CORPORATION AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements

(1) Description of the Company and Operating Environment

Astrotech Corporation (Nasdaq: ASTC) (Astrotech, the Company, we, us or our) is a commercial aerospace company that provides spacecraft payload processing and related services, designs and manufactures space hardware, and commercializes space technologies for use on Earth.

The Company has experience supporting both manned and unmanned missions to space with product and service support including space hardware design and manufacturing, research and logistics expertise, engineering and support services, and payload processing and integration. Through new Spacetechnology business initiatives such as 1st Detect and Astrogenetix, Astrotech is paving the way in the commercialization of space by translating space-based technology into terrestrial applications.

Our Business Units

Astrotech Space Operations (ASO)

ASO is a leading commercial supplier of satellite launch processing services in the United States. ASO provides processing support for government and commercial customers for their complex communication, earth observation and deep space satellites. ASO's spacecraft processing capabilities are among the elite in the industry, with ideally located facilities that can support the largest five-meter class satellites, encompassing the majority of U.S. based satellite preparation services. ASO has provided launch processing support for government and commercial customers for more than a quarter century, successfully processing more than 297 spacecraft without negatively impacting a customer launch schedule.

Spacetechnology

Our Spacetechnology business unit is an incubator intended to develop space-industry technologies into commercial applications to be sold to consumers and industry. Spacetechnology is currently working on two business initiatives: 1st Detect Corporation and Astrogenetix, Inc. 1st Detect's business began under a Space Act Agreement with the National Aeronautics and Space Administration (NASA) for a chemical detection unit to be used on the International Space Station. 1st Detect engineers are developing a Miniature Chemical Detector, based on ion trap mass spectrometry. With the introduction of our first product, the MMS-1000TM, we believe 1st Detect meets an unmet market demand by providing a rapid, lightweight, battery-powered, durable and inexpensive mass spectrometer. Astrogenetix is a biotechnology company created to use the unique environment of space to discover and develop novel therapeutic products. A natural extension of the many years of experience preparing, launching, and operating scientific payloads in space, Astrogenetix is in the process of developing products from microgravity discoveries.

The Company's significant legal entities include Astrotech Space Operations, Inc., 1st Detect Corporation and Astrogenetix, Inc.

(2) Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared by Astrotech Corporation in accordance with United States Generally Accepted Accounting Principles (GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by United States GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation have been included. Operating results for the nine months ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ending June 30, 2012. These financial statements should be read in conjunction with the financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended June 30, 2011.

Table of Contents**(3) Noncontrolling Interest**

In January 2010, restricted shares of Astrotech subsidiaries, 1st Detect and Astrogenetix, were granted to certain employees, directors and officers, resulting in Astrotech owning less than 100% of the subsidiaries. The Company applied noncontrolling interest accounting for the period ended March 31, 2012, which requires us to clearly identify the noncontrolling interest in the balance sheets and income statements. We disclose three measures of net income (loss): net income (loss), net income (loss) attributable to noncontrolling interest, and net income (loss) attributable to Astrotech Corporation. Our operating cash flows in our consolidated statements of cash flows reflect net income (loss); while our basic and diluted net income (loss) per share calculations reflect net income (loss) attributable to Astrotech Corporation.

	(In thousands)
Beginning balance at June 30, 2011	\$ 1,921
Net income (loss) attributable to noncontrolling interest	(486)
State of Texas funding (See Note 11)	900
Capital contribution	330
Stock based compensation expense	29
Ending balance at March 31, 2012	\$ 2,694

As of March 31, 2012, the Company's share of income and losses is 86% for 1st Detect and 84% for Astrogenetix.

(4) Net Income (loss) per Share

Basic net income (loss) per share is computed on the basis of the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is computed on the basis of the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method and the if-converted method. Dilutive potential common shares include outstanding stock options and shared-based awards. Reconciliation and the components of basic and diluted net income (loss) per share are as follows (in thousands, except per share data):

	Three Months Ended March 31, 2012		Nine Months Ended March 31, 2011	
Numerator:				
Net income (loss) attributable to Astrotech Corporation, basic and diluted	\$ 1,014	\$ (446)	\$ (1,438)	\$ (3,171)
Denominator:				
Denominator for basic net income (loss) per share attributable to Astrotech Corporation weighted average common stock outstanding	18,764	17,958	18,448	17,744
Dilutive common stock equivalents common stock options and share-based awards	388			
Denominator for diluted net income (loss) per share attributable to Astrotech Corporation weighted average common stock outstanding and dilutive common stock equivalents	19,152	17,958	18,448	17,744
Basic net income (loss) per share attributable to Astrotech Corporation	\$ 0.05	\$ (0.02)	\$ (0.08)	\$ (0.18)
Diluted net income (loss) per share attributable to Astrotech Corporation	\$ 0.05	\$ (0.02)	\$ (0.08)	\$ (0.18)

Options to purchase 794,100 shares of common stock at exercise prices ranging from \$0.71 to \$24.10 per share outstanding, for the three months ended March 31, 2012, were not included in diluted net income (loss) per share, as the impact to net income (loss) per share is anti-dilutive. Options to purchase 1,147,850 shares of common stock at exercise prices ranging from \$0.30 to \$24.10 per share outstanding, for the nine

Edgar Filing: ASTROTECH Corp \WA\ - Form 10-Q

months ended March 31, 2012, were not included in diluted net income (loss) per share, as the impact to net income (loss) per share is anti-dilutive. Options to purchase 377,350 shares of common stock at exercise prices ranging from \$0.30 to \$24.00 per share outstanding for the three and nine months ended March 31, 2011, were not included in diluted net income (loss) per share as the impact to net income (loss) per share is anti-dilutive.

Table of Contents**(5) Revenue Recognition**

Astrotech recognizes revenue employing several generally accepted revenue recognition methodologies across its business units. The methodology used is based on contract type and the manner in which products and services are provided.

Revenue generated by Astrotech's payload processing facilities is recognized ratably over the occupancy period of the spacecraft while in the Astrotech facilities. The percentage-of-completion method is used for all contracts where incurred costs can be reasonably estimated and successful completion can be reasonably assured at inception. Changes in estimated costs to complete and provisions for contract losses are recognized in the period they become known. Revenue for the sale of commercial products is recognized at shipment.

A Summary of Revenue Recognition Methods

Services/Products Provided	Contract Type	Method of Revenue Recognition
Payload Processing Facilities	Firm Fixed Price Mission Specific	Ratably, over the occupancy period of a satellite within the facility from arrival through launch
Construction Contracts	Firm Fixed Price	Percentage-of-completion based on costs incurred
Engineering Services	Cost Reimbursable Award/Fixed Fee	Reimbursable costs incurred plus award/fixed fee
Commercial Products	Specific Purchase Order Based	At shipment
Grant	Cost Reimbursable Award	As costs are incurred for related research and development expenses

Under certain contracts, we make expenditures for specific enhancements and/or additions to our facilities where the customer agrees to pay a fixed fee to deliver the enhancement or addition. We account for such agreements as a reduction in the cost of such investments and recognize any excess of amounts collected above the expenditure as revenue.

(6) Debt

In October 2010, we entered into a financing facility with a commercial bank providing a \$7.0 million term loan note and a \$3.0 million revolving credit facility. The \$7.0 million term loan terminates in October 2015, and the \$3.0 million revolving credit facility expires in October 2012. The term loan requires monthly payments of principal plus interest at the rate of prime plus 0.25%, but not less than 4.0%. The revolving credit facility allows multiple advances not to exceed \$3.0 million, based on eligible accounts receivable, and incurs interest at the rate of prime plus 0.25%, but not less than 4.0%. The bank financing facilities are secured by the assets of ASO, including accounts receivable, and require us to comply with designated covenants. At March 31, 2012 the balance of the term loan was \$6.5 million and there was no outstanding balance on the revolving credit.

The Company was in compliance with all covenants as of March 31, 2012.

(7) Fair Value Measurement

The accounting standard for fair value measurements defines fair value, establishes a market-based framework or hierarchy for measuring fair value, and expands disclosures about fair value measurements. The standard is applicable whenever assets and liabilities are measured and included in the financial statements at fair value.

Table of Contents

The fair value hierarchy established in the standard prioritizes the inputs used in valuation techniques into three levels as follows:

Level 1 Quoted prices in active markets for identical assets or liabilities.

Level 2 Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table presents the carrying amounts, estimated fair values and valuation input levels of certain of the Company's financial instruments as of March 31, 2012 and June 30, 2011 (in thousands):

	March 31, 2012		June 30, 2011		Valuation Inputs
	Carrying Amount	Fair Value	Carrying Amount	Fair Value	
Debt	\$ 6,503	\$ 6,503	\$ 6,770	\$ 6,770	Level 2

The carrying value of the Company's debt at March 31, 2012 approximates fair value based on rates available for similar debt available to comparable companies in the marketplace. The carrying amounts of the Company's Level 1 securities, which include cash and cash equivalents, accounts receivable, notes receivable and accounts payable approximate their fair market value due to the relatively short duration of these instruments.

(8) Asset Impairments

In the nine months ended March 31, 2012, the Company evaluated the future use of two historical SPACEHAB modules. Due to the retirement of the space shuttle program in the United States and the lack of alternative uses which could potentially generate cash flow, the Company recorded a non-cash impairment of \$0.2 million for the two SPACEHAB modules as the full aggregate carrying amount was deemed no longer recoverable.

(9) Business and Credit Risk Concentration

A substantial portion of our revenue has been generated under contracts with the U.S. Government. During the nine months ended March 31, 2012 and 2011, approximately 65% and 72%, respectively, of our revenues were generated under U.S. Government contracts. Accounts receivable totaled \$1.7 million at March 31, 2012, of which 72% was attributable to the U.S. Government.

The Company maintains funds in bank accounts that may exceed the limit insured by the Federal Deposit Insurance Corporation, or FDIC. In October 2008, the FDIC increased its insurance to \$250,000 per depositor, and to an unlimited amount for non-interest bearing accounts. The risk of loss attributable to these uninsured balances is mitigated by depositing funds in what we believe to be high credit quality financial institutions. The Company has not experienced any losses in such accounts.

(10) Segment Information

Management's primary financial and operating reviews focus on ASO, the core business unit. All intercompany transactions between business units have been eliminated in consolidation.

Key financial metrics for the three months ended March 31, 2012 are as follows (in thousands):

	Three Months Ended March 31, 2012		Three Months Ended March 31, 2011	
	Revenue	Income (loss) before income taxes	Revenue	Income (loss) before income taxes
Revenue and Income (loss)				
ASO	\$ 9,933	\$ 1,840	\$ 5,575	\$ 874

Edgar Filing: ASTROTECH Corp \WA\ - Form 10-Q

Spacetech	80	(955)	145	(1,563)
	\$ 10,013	\$ (885)	\$ 5,720	\$ (689)

Key financial metrics for the nine months ended March 31, 2012 are as follows (in thousands):

	Nine Months Ended March 31, 2012		Nine Months Ended March 31, 2011	
Revenue and Income (loss)	Revenue	Income (loss) before income taxes	Revenue	Income (loss) before income taxes
ASO	\$ 18,351	\$ 1,490	\$ 15,435	\$ 1,107
Spacetech	178	(3,397)	232	(5,043)
	\$ 18,529	\$ (1,907)	\$ 15,667	\$ (3,936)

Table of Contents

	March 31, 2012		June 30, 2011	
Assets	Fixed Assets, net	Total Assets	Fixed Assets, net	Total Assets
ASO	\$ 36,607	\$ 55,139	\$ 38,033	\$ 55,948
Spacetech	296	1,176	385	1,672
	\$ 36,903	\$ 56,315	\$ 38,418	\$ 57,620

(11) State of Texas Funding

In March 2010, the Texas Emerging Technology Fund awarded 1st Detect \$1.8 million for the development and marketing of the Miniature Chemical Detector, a portable mass spectrometer designed to serve the security, healthcare and industrial markets. In exchange for the award, 1st Detect granted a common stock purchase right and a note payable to the State of Texas. As of March 31, 2012, 1st Detect has received both \$0.9 million disbursements totaling the full amount of the award. The proceeds from the award can only be used to fund development of the Miniature Chemical Detector at 1st Detect, not for repaying existing debt or for use in other Company subsidiaries.

The common stock purchase right is exercisable at the first Qualifying Financing Event, which is essentially a change in control or third party equity investment in 1st Detect. The number of shares available to the State of Texas, at the price of par value, is calculated as the total disbursements (numerator) divided by the stock price established in the Qualifying Financing Event (denominator). If the first Qualifying Financing Event does not occur within 18 months of the agreement's effective date, the number of shares available for purchase will equal the total disbursements (numerator) divided by \$100 (denominator). At management's request, the deadline for calculating the equity conversion factor was extended by the State of Texas for an additional six months to September 30, 2012.

The note equals the disbursements to 1st Detect to date, accrues interest at 8% per year and cancels automatically at the earlier of (1) selling substantially all of the assets of 1st Detect, (2) selling more than 50% of common stock of 1st Detect or (3) March 2020. No payments of interest or principal are due on the note unless there is a default, which would occur if 1st Detect moves its operations or headquarters outside of Texas at any time before March 2020.

Management considers the likelihood of voluntarily repaying the note or of a default event as remote due to the fact that the covenants that would necessitate repayment are within the control of the Company. As such, the two \$0.9 million installments were accounted for as a contribution to equity in the nine months ended March 31, 2012. As of March 31, 2012, no default events have occurred.

(12) Equity and Other Long Term Incentive Plans***Equity Grants***

In August 2009, September 2009, and November 2009 the Compensation Committee of the Board of Directors granted directors, named executive officers and employees 1,650,000, 345,559 and 410,000, respectively, of restricted shares. The shares were issued from the 2008 Stock Incentive Plan, vest 33.33% a year over a three-year period and unvested shares are forfeited upon employee termination.

In September 2011, the Compensation Committee of the Board of Directors granted directors, named executive officers and employees 579,000 stock options designed to increase shareholder value by compensating employees over the long term. The options were issued from the 2008 and 2011 Stock Incentive Plans, vest upon the Company's stock achieving a closing price of \$1.50 and expire 10 years from grant date or upon employee termination.

In July 2011, the Compensation Committee of the Board of Directors granted a third party consultant 200,000 stock options intended to provide incentive which is aligned with management and the shareholders. The options were issued out of the 2011 Stock Incentive Plan, vest upon certain performance conditions and expire 7 years from grant date. Management considers the likelihood of the performance conditions being met as remote, and therefore no expense was recorded for the nine months ended March 31, 2011.

As of March 31, 2012, 26,818 shares of common stock were reserved for future grants under the 2008 Stock Incentive Plan and 1,386,000 shares of common stock reserved for future grant under the 2011 Stock Incentive Plan. In the nine months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.6 million and \$0.6 million, respectively, for restricted stock and stock options outstanding.

Table of Contents

Related Party Transactions

Director Compensation

In August 2009, the Board of Directors granted 525,000 restricted shares valued at \$0.6 million to directors from the 2008 Stock Incentive Plan. In August 2011, the Board of Directors granted 25,000 restricted shares valued at \$0.1 million to a director from the 2008 Stock Incentive Plan. The restricted shares vest 33.33% a year for three years and unvested shares are forfeited upon termination. Compensation expense of \$0.2 million was recorded in the nine months ended March 31, 2012 for these awards.

In September 2011, the Board of Directors granted 150,000 stock options valued at \$0.1 million to directors from the 2011 Stock Incentive Plan. The stock options vest upon the Company's stock achieving a closing price of \$1.50 and expire 10 years from grant date. Compensation expense of \$0.1 million was recorded in the nine months ended March 31, 2012.

Executive Compensation

1st Detect

In January 2010, an independent committee of the Board of Directors of 1st Detect approved a grant of 1,180 restricted stock shares, of which 75 have been subsequently cancelled, and 1,820 stock purchase warrants, of which 45 have been subsequently cancelled, to certain officers, directors and employees of 1st Detect. The awards will vest as follows, subject to earlier vesting upon the grantee's death or disability or in the event of a change of control of the Company: 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date. The restricted stock agreements and stock purchase warrants provide for forfeiture of unvested stock if the recipient is terminated or voluntarily ceases to perform services for 1st Detect, immediate vesting upon a change of control, and restrictions on and requirements as to transfer. The stock purchase warrants have an exercise price equal to the fair market value of 1st Detect's common stock on the date of grant as determined by an independent valuation firm.

The number of shares and warrants underlying each award to a named executive officer is as follows: Thomas B. Pickens III: 300 shares, 680 warrants; John Porter: 200 shares, 180 warrants. In the nine months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for restricted stock and warrants outstanding.

In September 2011, the Board of Directors of 1st Detect approved a grant of 965 stock options to certain officers, directors and employees of 1st Detect. The awards vest upon certain performance conditions being met and expire 10 years from grant date. The stock options have an exercise price equal to the fair market value of 1st Detect's common stock on the date of grant as determined by an independent valuation firm.

The number of options underlying each award to a named executive officer is as follows: Thomas B. Pickens III: 200 stock options; John Porter: 150 stock options. In the nine months ended March 31, 2012, the Company recognized compensation expense of \$0.1 million.

Assuming a business event occurred, then Thomas B. Pickens III would hold 10.9%, John Porter would hold 4.9% and the Company would hold 64.5% of the outstanding shares of 1st Detect. This assumed calculation is made without taking into account any dilution resulting from the State of Texas funding.

The restricted stock issuances resulted in noncontrolling interest, as described in Note 3.

Astrogenetix

In January 2010, an independent committee of the Board of Directors of Astrogenetix approved a grant of 1,550 restricted stock shares, of which 375 have been subsequently cancelled. There were 2,050 stock purchase warrants that were also granted to certain officers, directors and employees of Astrogenetix, of which 50 have been subsequently cancelled. The awards will vest as follows, subject to earlier vesting upon the grantee's death or disability or in the event of a change of control of the Company: 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date. The restricted stock agreements and stock purchase warrants provide for forfeiture of unvested stock if the recipient is terminated or voluntarily ceases to perform services for Astrogenetix, immediate vesting upon a change of control, and restrictions on and requirements as to transfer. The stock purchase warrants have an exercise price equal to the fair market value of Astrogenetix's common stock on the date of grant as determined by an independent valuation firm.

Table of Contents

The number of shares and warrants underlying each award to a named executive officer is as follows: Thomas B. Pickens III: 500 shares, 1,000 warrants; John Porter: 400 shares, 800 warrants. In the three months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for restricted stock and warrants outstanding.

Assuming a business event occurred which resulted in the vesting of all restricted stock and stock purchase warrants, then Thomas B. Pickens III would hold 16.3%, John Porter would hold 13.1% and the Company would hold 65.4% of the outstanding shares of Astrogenetix.

The restricted stock issuances resulted in noncontrolling interest, as described in Note 3.

Stock Options

In the three months ended September 30, 2011, 779,000 stock options were granted to employees, directors and consultants. At March 31, 2012 and 2011, there were \$0.3 million and \$0.1 million, respectively, of total unrecognized compensation costs related to non-vested stock options, which is expected to be recognized over a weighted average period of 7.9 years.

In the three months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for stock options outstanding.

The Company's stock options activity for the three months ended March 31, 2012 was as follows:

	Shares (in thousands)	Weighted Average Exercise Price
Outstanding at December 31, 2011	1,148	\$ 0.79
Granted		
Exercised		
Cancelled or expired		
Outstanding at March 31, 2012	1,148	\$ 0.79

In the nine months ended March 31, 2012, we recognized compensation expense of \$0.1 million for stock options outstanding. In the nine months ended March 31, 2011, no compensation expense was recognized for stock options outstanding.

The Company's stock options activity for the nine months ended March 31, 2012 was as follows:

	Shares (in thousands)	Weighted Average Exercise Price
Outstanding at June 30, 2011	377	\$ 1.28
Granted	779	0.79
Exercised		
Cancelled or expired	(8)	22.64
Outstanding at March 31, 2012	1,148	\$ 0.79

Restricted Stock

At March 31, 2012 and 2011, there were \$0.3 million and \$1.1 million respectively, of unrecognized compensation costs related to restricted stock, which is expected to be recognized over a weighted average period of 0.5 years.

Edgar Filing: ASTROTECH Corp \WA\ - Form 10-Q

In the three months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.2 million and \$0.2 million, respectively, for restricted stock outstanding.

Table of Contents

The Company's restricted stock activity for the three months ended March 31, 2012 was as follows:

	Shares (in thousands)	Weighted Average Grant- Date Fair Value
Non-vested at December 31, 2011	706	\$ 1.10
Granted		
Vested	(25)	0.58
Cancelled or expired	(1)	1.22
Non-vested at March 31, 2012	680	\$ 1.12

In the nine months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.6 million and \$0.6 million, respectively, for restricted stock outstanding.

The Company's restricted stock activity for the nine months ended March 31, 2012 was as follows:

	Shares (in thousands)	Weighted Average Grant- Date Fair Value
Non-vested at June 30, 2011	1,365	\$ 1.14
Granted	25	0.75
Vested	(700)	1.15
Cancelled or expired	(10)	1.22
Non-vested at March 31, 2012	680	\$ 1.12

Stock Options and Warrants for 1st Detect

At March 31, 2012 there was \$0.1 million of unrecognized compensation costs related to stock options, which is expected to be recognized over a weighted average period of 9.5 years. At March 31, 2012 the warrants were fully vested and there is no additional compensation expense to be recognized related to warrants. At March 31, 2011 there was \$0.1 million of unrecognized compensation costs related to stock options and warrants.

In the three months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for stock options and warrants outstanding.

1st Detect stock options and warrants activity for the three months ended March 31, 2012 was as follows:

Weighted

	Shares	Average Grant- Date Fair Value
Outstanding at December 31, 2011	2,740	\$ 212.00
Granted		
Exercised		
Cancelled or expired		
Outstanding at March 31, 2012	2,740	\$ 212.00

In the nine months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for stock options and warrants outstanding.

Table of Contents

1st Detect stock options and warrants activity for the nine months ended March 31, 2012 was as follows:

	Shares	Weighted Average Grant- Date Fair Value
Outstanding at June 30, 2011	1,820	\$ 212.00
Granted	965	212.00
Exercised		
Cancelled or expired	(45)	212.00
Outstanding at March 31, 2012	2,740	\$ 212.00

Restricted Stock for 1st Detect

At March 31, 2012 the awards were fully vested and there is no additional compensation expense to be recognized related to restricted stock. At March 31, 2011 there were \$0.1 million of unrecognized compensation costs related to restricted stock.

In the three months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for restricted stock outstanding.

1st Detect restricted stock activity for the three months ended March 31, 2012 was as follows:

	Shares	Weighted Average Grant- Date Fair Value
Non-vested at December 31, 2011	515	\$ 212.00
Granted		
Vested	(515)	212.00
Cancelled or expired		
Non-vested at March 31, 2012		\$

In the nine months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for restricted stock outstanding.

1st Detect restricted stock activity for the nine months ended March 31, 2012 was as follows:

Shares	Weighted Average Grant- Date
--------	---------------------------------------

		Fair Value
Non-vested at June 30, 2011	590	\$ 212.00
Granted		
Vested	(515)	212.00
Cancelled or expired	(75)	212.00
Non-vested at March 31, 2012		\$

Warrants for Astrogenetix

At March 31, 2012 the warrants were fully vested and there is no additional compensation expense to be recognized related to warrants. At March 31, 2011 there was \$0.1 million of unrecognized compensation costs related to warrants.

In the three months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for warrants outstanding.

Table of Contents

Astrogenetix warrant activity for the three months ended March 31, 2012 was as follows:

	Shares	Weighted Average Grant- Date Fair Value
Outstanding at December 31, 2011	2,000	\$ 167.00
Granted		
Exercised		
Cancelled or expired		
Outstanding at March 31, 2012	2,000	\$ 167.00

In the nine months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for warrants outstanding.

Astrogenetix warrant activity for the nine months ended March 31, 2012 was as follows:

	Shares	Weighted Average Grant- Date Fair Value
Outstanding at June 30, 2011	2,050	\$ 167.00
Granted		
Exercised		
Cancelled or expired	(50)	167.00
Outstanding at March 31, 2012	2,000	\$ 167.00

Restricted Stock for Astrogenetix

At March 31, 2012 the awards were fully vested and there is no additional compensation expense to be recognized related to restricted stock. At March 31, 2011 there were \$0.1 million respectively, of unrecognized compensation costs related to restricted stock.

In the three months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for restricted stock outstanding.

Astrogenetix restricted stock activity for the three months ended March 31, 2012 was as follows:

Shares	Weighted Average Grant-
--------	-------------------------------

		Date Fair Value
Non-vested at December 31, 2011	550	\$ 167.00
Granted		
Vested	(550)	167.00
Cancelled or expired		
Non-vested at March 31, 2012		\$

In the nine months ended March 31, 2012 and 2011, we recognized compensation expense of \$0.1 million and \$0.1 million, respectively, for restricted stock outstanding.

Astrogenetix restricted stock activity for the nine months ended March 31, 2012 was as follows:

	Shares	Weighted Average Grant- Date Fair Value
Non-vested at June 30, 2011	625	\$ 167.00
Granted		
Vested	(550)	167.00
Cancelled or expired	(75)	167.00
Non-vested at March 31, 2012		\$

Table of Contents

(13) Income Taxes

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are more likely than not to be realized. As of March 31, 2012, the Company has established a full valuation allowance against all of its net deferred tax assets.

FASB ASC 740, *Income Taxes* (FASB ASC 740) addresses the accounting for uncertainty in income taxes recognized in an entity's financial statements and prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken on a tax return. As of March 31, 2012, the Company has a liability of \$60,000 (\$39,000 net of federal benefit) for unrecognized tax benefits.

For the three and nine months ended March 31, 2012 and 2011, the Company's effective tax rate differed from the federal statutory rate of 35%, primarily due to recording changes to the valuation allowance placed against its net deferred tax assets.

The Company files consolidated returns for federal, California, Florida, and Texas income and franchise taxes.

The Company is currently under examination by the Internal Revenue Service for the fiscal years ended June 30, 2008 through 2010. Loss carryovers are generally subject to modification by tax authorities until 3 years after they have been utilized; as such, the Company is subject to examination for the fiscal years ended 2000 through present for federal purposes and fiscal years ended 2006 through present for state purposes.

(14) Early Termination of Cost Plus Award Fee Contract

The Company and ARES have resolved certain issues relative to the early termination of the subcontract in May 2008, including, but not limited to, a receivable from ARES under this agreement totaling \$1.4 million. The Company wrote off \$0.1 million of unbilled receivables in connection with this agreement in the period ended June 30, 2010. In July 2010, the Company received \$1.2 million from ARES. In February 2012, the Company received \$0.1 million from ARES. The remaining \$0.1 million balance is expected to be paid upon completion of the 2007 through 2008 governmental audits by the DCAA.

(15) Purchase of Astrotech Securities

Repurchases of Astrotech securities under the Company's securities repurchase program may be made from time-to-time, in the open market, through block trades or otherwise in accordance with applicable regulations of the Securities and Exchange Commission. Depending on market conditions and other factors, these purchases may be commenced or suspended at any time or from time-to-time without prior notice. Additionally, the timing of such transactions will depend on other corporate strategies and will be at the discretion of the management of the Company.

As of March 31, 2012, we had repurchased 311,660 shares of common stock at a cost of \$0.2 million, which represents an average cost of \$0.76 per share. Additionally, during fiscal year 2009 the Company repurchased \$1.1 million of Senior Convertible Notes payable. As a result, the Company is authorized to repurchase an additional \$5.7 million of Astrotech securities.

(16) NASDAQ Listing Qualifications

In February 2012, the Company received a second compliance notice from The NASDAQ Stock Market ("NASDAQ") regarding the Company's failure to maintain the minimum bid price for continued listing. However, the NASDAQ staff has determined that the Company is eligible for an additional 180 day grace period, or until August 27, 2012, to regain compliance. NASDAQ's determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the NASDAQ Capital Market, with the exception of the bid price requirement, and the Company's written notice to NASDAQ of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.

Table of Contents

The Company previously received a written notification from NASDAQ on August 30, 2011, indicating that the minimum bid price of the Company's common stock had fallen below \$1.00 for 30 consecutive trading days and that it was therefore not in compliance with NASDAQ Listing Rule 5550(a)(2).

Table of Contents

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements for purposes of federal and state securities laws. Forward-looking statements may include the words may, will, plans, believes, estimates, expects, intends and other similar expressions. Such statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected in the statements. Such risks and uncertainties include, but are not limited to:

The effect of economic conditions in the United States or other space faring nations that could impact our ability to access space and support or gain customers;

Our ability to raise sufficient capital to meet our long and short-term liquidity requirements;

Our ability to successfully pursue our business plan and execute our strategy;

Whether we will fully realize the economic benefits under our customer contracts;

Technological difficulties and potential legal claims arising from any technological difficulties;

Product demand and market acceptance risks, including our ability to develop and sell products and services to be used by governmental or commercial customers;

Uncertainty in government funding and support for key space programs;

The impact of competition on our ability to win new contracts;

Uncertainty in securing reliable and consistent access to space, including the International Space Station;

Delays in the timing of performance of our contracts;

Our ability to control costs;

Our ability to meet technological development milestones and overcome development challenges; and

Risks described in the Risk Factors section of our 2011 Annual Report on Form 10-K. Although we believe that the assumptions underlying our forward-looking statements are reasonable, any of the assumptions could be inaccurate, and, therefore, we cannot assure you that the forward-looking statements included in this Quarterly Report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in our forward-looking statements, the inclusion of such information should not

be regarded as a representation by us or any other person that our objectives and plans will be achieved. Some of these and other risks and uncertainties that could cause actual results to differ materially from such forward-looking statements are more fully described in the Risk Factors included in Part II Item 1A of this Report and Part I, Item 1A of our 2011 Annual Report on 10-K and elsewhere in this Quarterly Report on Form 10-Q or in the documents incorporated by reference herein. Except as may be required by applicable law, we undertake no obligation to publicly update or advise of any change in any forward-looking statement, whether as a result of new information, future events or otherwise. In making these statements, we disclaim any obligation to address or update each factor in future filings with the Securities and Exchange Commission (SEC) or communications regarding our business or results, and we do not undertake to address how any of these factors may have caused changes to discussions or information contained in previous filings or communications. In addition, any of the matters discussed above may have affected our past results and may affect future results, so that our actual results may differ materially from those expressed in this Quarterly Report on Form 10-Q and in prior or subsequent communications.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following information should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in Part I, Item 1 of this Report, and the Risk Factors included in Part II Item 1A of this Report and Part I, Item 1A of our 2011 Annual Report on Form 10-K.

Overview

Astrotech Corporation was formed in 1984 to leverage the environment of space for commercial purposes. For nearly 30 years, the Company and its subsidiaries has remained a crucial player in space commerce activities. We have supported the launch of 23 shuttle missions and more than 297 spacecraft, building space hardware and processing facilities, and preparing and processing scientific research for microgravity.

We offer products and services in the following areas:

Facilities and support services necessary for the preparation of satellites and payloads for launch.

Design and fabrication of equipment and hardware for space launch activities.

Propellant services support for spacecraft.

Commercialization of space-based technologies into real-world applications.

Our Business Units

Astrotech Space Operations (ASO)

ASO provides support for its government and commercial customers to successfully process complex communication, earth observation and deep space satellites in preparation for their launch on a variety of launch vehicles. Processing activities include satellite ground transportation; pre-launch hardware integration and testing; satellite encapsulation, fueling, launch pad delivery; and communication linked launch control. Our ASO facilities can accommodate five meter class satellites encompassing the majority of U.S. based satellite preparation services. ASO's service capabilities also include designing, building spacecraft processing equipment and facilities. Additionally, ASO provides propellant services including designing, building and testing propellant service equipment for servicing spacecraft. ASO accounted for 99% of our consolidated revenues for the nine months ended March 31, 2012. Revenue for our ASO business unit is generated primarily from various fixed-priced contracts with launch service providers in both the commercial and government markets and from design and fabrication of space launch equipment. The services and facilities we provide to our customers support the final assembly, checkout, and countdown functions associated with preparing a spacecraft for launch. The revenue and cash flows generated from our ASO operations are related to the number of spacecraft launches and the costs incurred to build space launch hardware. Other factors that have impacted, and are expected to continue to impact earnings and cash flows for this business include:

Our ability to control our capital expenditures, which primarily are limited to modifications to accommodate payload processing for new launch vehicles and upgrading building infrastructure.

The continuing limited availability of competing facilities at the major domestic launch sites that can offer comparable services, leading to an increase in government and commercial use of our services.

Our ability to complete customer specified facility modifications within budgeted costs and time commitments.

Our ability to control and reduce costs in order to maximize profitability of our fixed-priced contracts.

Table of Contents**Spacetechn**

Our other business unit is an incubator intended to commercialize space-industry technologies into commercial applications to be sold to consumers and industry. The 1st Detect Miniature Chemical Detector and the Astrogenetix microgravity processing platform are initiatives developed under our Spacetechn business unit. 1st Detect recently announced the launch of the MMS-1000™, a low power, chemical detection device designed primarily for the laboratory testing market. 1st Detect has been awarded a Developmental Testing and Evaluation designation from the U.S. Department of Homeland Security as a promising anti-terrorism technology, and is the recipient of a Phase I and Phase II award from the U.S. Army's Chemical and Biological Defense (CBD) Small Business Innovation Research (SBIR) Program. Following the successful execution of the Phase I SBIR, 1st Detect was awarded a \$0.8 million Phase II SBIR contract from the Joint Science and Technology Office for Chemical and Biological Defense. Additionally, 1st Detect received a \$1.8 million award from the Texas Emerging Technology Fund in March 2010. Astrogenetix is a biotechnology company formed to commercialize products processed in the unique environment of microgravity. Astrogenetix has pursued an aggressive space access strategy to take advantage of the Space Shuttle program prior to its retirement, which occurred in 2011. This strategy gave Astrogenetix unprecedented access to research in microgravity, as the company flew twelve experiments over a three year period. Astrogenetix is currently researching a Salmonella vaccine as part of the ongoing commercialization strategy. Concurrently, Astrogenetix is working on the continued development of a vaccine target for methicillin-resistant Staphylococcus aureus (MRSA) based on discoveries made in microgravity.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles for interim financial statements. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates and assumptions are reviewed periodically. Actual results may differ from these estimates under different assumptions or conditions.

Management believes there have been no significant changes during the nine months ended March 31, 2012 to the items that we disclosed as our critical accounting policies and estimates in Management's Discussion and Analysis of Financial Condition and Results of Operations in our 2011 10-K.

Results of Operation**Three months ended March 31, 2012 compared to three months ended March 31, 2011:**

Selected consolidated financial data for the three months ended March 31, 2012 and 2011 is as follows (dollars in thousands):

	Three Months Ended March 31,	
	2012	2011
Revenue	\$ 10,013	\$ 5,720
Cost of revenue	6,770	3,142
Gross profit	3,243	2,578
Gross margin	32%	45%
Selling, general and administrative	1,814	1,941
Research and development	475	1,256
Operating expenses	2,289	3,197
Interest and other expense, net	(69)	(70)
Income tax expense	(5)	(5)

Consolidated net income (loss)	880	(694)
Less: Net loss attributable to noncontrolling interest	(134)	(248)
Net income (loss) attributable to Astrotech Corporation	\$ 1,014	\$ (446)

Revenue. Total revenue increased to \$10.0 million for the three months ended March 31, 2012 from \$5.7 million for the three months ended March 31, 2011. This increase is primarily attributable to revenue earned on the fabrication of the Ground Support Equipment (GSE) for the U.S. Government.

Table of Contents

Gross Profit. Gross profit increased to \$3.2 million for the three months ended March 31, 2012 from \$2.6 million for the three months ended March 31, 2011. The increase in both revenue and cost of revenue for the three months ended March 31, 2012 is primarily attributable to the fabrication of GSE for the U.S. Government.

Selling, General and Administrative Expense. Selling, general and administrative expense decreased to \$1.8 million for the three months ended March 31, 2012 from \$1.9 million for the three months ended March 31, 2011. The decrease was primarily attributable to a reduction in variable legal and consulting fees.

Research and Development Expense. Research and development expense decreased to \$0.5 million for the three months ended March 31, 2012 from \$1.3 million for the three months ended March 31, 2011. This decrease is primarily due to a shift in investment from Astrogenetix to 1st Detect due to the retirement of the space shuttle program in the United States, and due to the need of capital to fund research and development in the 1st Detect Miniature Chemical Detector. The decrease is also a result of the lease of two 1st Detect evaluation units to potential customers, which was recorded as an offset to research and development expense.

Nine months ended March 31, 2012 compared to nine months ended March 31, 2011:

Selected consolidated financial data for the nine months ended March 31, 2012 and 2011 is as follows (dollars in thousands):

	Nine Months Ended March 31,	
	2012	2011
Revenue	\$ 18,529	\$ 15,667
Cost of revenue	12,804	10,066
Gross profit	5,725	5,601
Gross margin	31%	36%
Selling, general and administrative	5,451	6,367
Research and development	1,979	2,962
Operating expenses	7,430	9,329
Interest and other expense, net	(202)	(208)
Income tax expense	(17)	(16)
Consolidated net loss	(1,924)	(3,952)
Less: Net loss attributable to noncontrolling interest	(486)	(781)
Net loss attributable to Astrotech Corporation	\$ (1,438)	\$ (3,171)

Revenue. Total revenue increased to \$18.5 million for the nine months ended March 31, 2012 from \$15.7 million for the nine months ended March 31, 2011. This increase is primarily attributable to revenue earned on the fabrication of the GSE for the U.S. Government.

Gross Profit. Gross profit increased to \$5.7 million for the nine months ended March 31, 2012 from \$5.6 million for the nine months ended March 31, 2011. The increase in both revenue and cost of revenue for the three months ended March 31, 2012 is primarily attributable to the fabrication of the GSE for the U.S. Government.

Selling, General and Administrative Expense. Selling, general and administrative expense decreased to \$5.5 million for the nine months ended March 31, 2012 from \$6.4 million for the nine months ended March 31, 2011. The decrease was primarily attributable to a reduction in variable outside legal and consulting fees, severance and employee incentive compensation.

Research and Development Expense. Research and development expense decreased to \$2.0 million for the nine months ended March 31, 2012 from \$3.0 million for the nine months ended March 31, 2011. This decrease is primarily due to a shift in investment from Astrogenetix to 1st Detect due to the retirement of the space shuttle program in the United States, and due to the need of capital to fund research and development in the 1st Detect Miniature Chemical Detector. The decrease is also a result of the lease of two 1st Detect evaluation units to potential customers, which was recorded as an offset to research and development expense.

Table of Contents**Liquidity and Capital Resources**

The following is a summary of the change in our cash and cash equivalents (in thousands):

	Nine Months Ended March 31,	
	2012	2011
Net cash provided by operating activities	\$ 598	\$ 1,488
Net cash used in investing activities	(385)	(621)
Net cash provided by (used in) financing activities	633	(1,463)
Net change in cash and cash equivalents	\$ 846	\$ (596)

Cash and Cash Equivalents

At March 31, 2012, we had cash and cash equivalents of \$15.8 million and our working capital was approximately \$7.4 million. Cash and cash equivalents increased approximately \$0.8 million during the nine months ended March 31, 2012. At March 31, 2011, we had cash and cash equivalents of \$7.5 million and our working capital was approximately \$6.6 million.

Operating Activities

Net cash provided by operations was \$0.6 million for the nine months ended March 31, 2012 compared to cash provided by operations of \$1.5 million for the nine months ended March 31, 2011. The decrease in cash flow provided by operations between the periods was primarily due to the timing of payments of accounts payable and a reduction in deferred revenue cash collections on customer contracts, which were partially offset by the timing of payments collected in accounts receivable.

During the nine months ended March 31, 2012, the decrease in deferred revenue and the increase in accounts payable and accrued liabilities were primarily attributable to the GSE project. During the nine months ended March 31, 2011, the decrease in accounts receivable was primarily driven by the receipt of \$1.2 million relating to the ARES contract.

Investing Activities

Net cash used in investing activities was \$0.4 million for the nine months ended March 31, 2012 compared to \$0.6 million for the nine months ended March 31, 2011. Our investing activities are driven primarily by the timing of capital expenditures for our payload processing facilities.

Financing Activities

Cash provided by financing activities was \$0.6 million for the nine months ended March 31, 2012 compared to cash used in financing activities of \$1.5 million for the nine months ended March 31, 2011. In the nine months ended March 31, 2012, 1st Detect received the second installment of \$0.9 million from the Texas Emerging Technology Fund, which was used to fund the continued development of the 1st Detect Miniature Chemical Detector. In the nine months ended March 31, 2011 the Company repaid the Senior Convertible Notes of \$5.1 million, retired the legacy term loan of \$3.4 million and entered into the current term loan of \$7.0 million.

Debt

In October 2010, we entered into a financing facility with a commercial bank providing a \$7.0 million term loan note and a \$3.0 million revolving credit facility. The \$7.0 million term loan terminates in October 2015, and the \$3.0 million revolving credit facility expires October 2012. The term loan requires monthly payments of principal plus interest at the rate of prime plus 0.25%, but not less than 4.0%. The revolving credit facility allows multiple advances not to exceed \$3.0 million, based on eligible accounts receivable, and incurs interest at the rate of prime plus 0.25%, but not less than 4.0%. The bank financing facilities are secured by the assets of ASO, including accounts receivable, and require us to comply with designated covenants. At March 31, 2012 the balance of the term loan was \$6.5 million and there was no outstanding balance on the revolving credit facility.

Table of Contents

The Company was in compliance with all covenants as of March 31, 2012.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to amounts that are more likely than not to be realized. As of March 31, 2012, the Company has established a full valuation allowance against all of its net deferred tax assets.

FASB ASC 740, *Income Taxes* (FASB ASC 740) addresses the accounting for uncertainty in income taxes recognized in an entity's financial statements and prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken on a tax return. As of March 31, 2012, the Company has a liability of \$60,000 (\$39,000 net of federal benefit) for unrecognized tax benefits.

For the three and nine months ended March 31, 2012 and 2011, the Company's effective tax rate differed from the federal statutory rate of 35%, primarily due to recording changes to the valuation allowance placed against its net deferred tax assets.

The Company files consolidated returns for federal, California, Florida, and Texas income and franchise taxes.

The Company is currently under examination by the Internal Revenue Service for the fiscal years ended June 30, 2008 through 2010. Loss carryovers are generally subject to modification by tax authorities until 3 years after they have been utilized; as such, the Company is subject to examination for the fiscal years ended 2000 through present for federal purposes and fiscal years ended 2006 through present for state purposes.

Off-Balance Sheet Arrangements

We do not have any significant off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have no material changes to the disclosure made on this matter in our 2011 Annual Report on Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (Exchange Act), which are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of the end of the period covered by this Quarterly Report. Based on the evaluation and criteria of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective.

(b) Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Exchange Act Rule 13a-15(d) during the quarter ended March 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Currently, the Company is not a party to any material pending legal proceedings, which in management's opinion, would have a material adverse effect on our business, financial condition, or results of operation.

ITEM 1A. RISK FACTORS

There have been no material changes in the risk factors described in our 2011 Annual Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the quarter ended March 31, 2012, we did not issue any unregistered securities or repurchase any of our securities.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

The following exhibits are filed herewith:

Exhibit No.	Description
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
32	Certification pursuant to Rule 13a-14(b) of the Securities and Exchange Act of 1934.
101	The following financial information from the Company's Quarterly Report on Form 10-Q, for the period ended March 31, 2012, formatted in eXtensible Business Reporting Language: (i) Unaudited Condensed Consolidated Balance Sheets, (ii) Unaudited Condensed Consolidated Statements of Operations, (iii) Unaudited Condensed Consolidated Statements of Cash Flows, (v) Notes to Unaudited Condensed Consolidated Financial Statements. (1)

Table of Contents

- (1) Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Astrotech Corporation

Date: May 7, 2012

/s/ Thomas B. Pickens III
Thomas B. Pickens III
Chief Executive Officer

/s/ John M. Porter
John M. Porter
Senior Vice President and Chief Financial Officer